Korean J Gastroenterol.  2018 Apr;71(4):244-245. 10.4166/kjg.2018.71.4.244.

Novel Palliative Chemotherapy in Patients with Metastatic Pancreatic Cancer: PEGPH20

• Kim DU

• KMID: 2409895
• DOI: http://doi.org/10.4166/kjg.2018.71.4.244

Abstract

No abstract available.

MeSH Terms

Drug Therapy*
Humans
Pancreatic Neoplasms*

Reference

References

1. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002; 169:2756–2761.

2. Zhao F, Obermann S, von Wasielewski R, et al. Increase in frequency of myeloid-derived suppressor cells in mice with spontaneous pancreatic carcinoma. Immunology. 2009; 128:141–149.

3. Toole BP, Slomiany MG. Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells. Semin Cancer Biol. 2008; 18:244–250.

4. Shepard HM, Frost GI, Rybak ME, et al. Targeting hyaluronan (HA) in the tumor stroma: translational evaluation of pegylated hyaluronidase (PEGPH20) in animal models and patients with advanced solid tumors. J Clin Oncol. 2012; 30(4_suppl):249.

5. Thompson CB, Shepard HM, O'Connor PM, et al. Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. Mol Cancer Ther. 2010; 9:3052–3064.

6. Hingorani SR, Zheng L, Bullock AJ, et al. HALO 202: randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine versus nab-paclitaxel/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma. J Clin Oncol. 2018; 36:359–366.

7. Infante JR, Korn RL, Rosen LS, et al. Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours. Br J Cancer. 2018; 118:153–161.